Scholarlink

Background <p>Mitochondrial iron handling and immune surveillance are intertwined in tumor biology. Mitochondrial ferritin (FTMT) buffers redox-active iron in mitochondria, while MICB is an NKG2D ligand that can promote anti-tumor cytotoxicity when expressed on tumor cells. However, whether FTMT has a causal relationship with non-small cell lung cancer (NSCLC) risk—and how this might connect to MICB biology—remains uncertain.</p> Methods <p>We applied a genetics–omics–validation workflow. We conducted two-sample Mendelian randomization (MR) and mediation MR using plasma proteomic pQTL summary statistics (UK Biobank Pharma Proteomics Project) and NSCLC GWAS summary statistics from FinnGen (R12). To contextualize results in the tumor microenvironment, we interrogated single-cell RNA-seq datasets via TISCH2 and explored pharmacogenomic associations using GDSC. Mechanistic plausibility was tested in A549 lung adenocarcinoma cells using FTMT overexpression followed by qPCR and Western blotting.</p> Results <p>Genetically predicted higher FTMT levels were associated with reduced NSCLC risk (IVW OR per 1-SD increase ≈ 0.91). Mediation MR suggested that MICB-related signals accounted for a modest proportion of the FTMT effect. Single-cell analyses showed FTMT enrichment in malignant epithelial cells, whereas MICB was expressed across multiple compartments. In vitro, FTMT overexpression increased MICB mRNA and protein abundance.</p> Conclusions <p>Integrating genetic evidence, tumor-context transcriptomics, and cell-based validation supports FTMT as a protective factor for NSCLC and points to a mitochondrial–immune axis involving MICB. Observed differences between blood-based genetic proxies and tumor-cell experiments are consistent with context-dependent regulation (e.g., circulating MICB can reflect shedding, whereas tumor-cell MICB reflects surface stress-ligand programs).</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

An integrative framework combining Mendelian randomization, single-cell profiling, and experimental validation identifies FTMT as a mitochondrial–immune regulator in non-small cell lung cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月16日

查看全文
  • Shouyong Xiao,
  • Siyun Wu,
  • Xianfeng Shao,
  • Ming Chao,
  • Quibo Huang,
  • Chen Ke,
  • Jiaping Chen,
  • Guangjian Li,
  • Lianhua Ye

摘要

Background

Mitochondrial iron handling and immune surveillance are intertwined in tumor biology. Mitochondrial ferritin (FTMT) buffers redox-active iron in mitochondria, while MICB is an NKG2D ligand that can promote anti-tumor cytotoxicity when expressed on tumor cells. However, whether FTMT has a causal relationship with non-small cell lung cancer (NSCLC) risk—and how this might connect to MICB biology—remains uncertain.

Methods

We applied a genetics–omics–validation workflow. We conducted two-sample Mendelian randomization (MR) and mediation MR using plasma proteomic pQTL summary statistics (UK Biobank Pharma Proteomics Project) and NSCLC GWAS summary statistics from FinnGen (R12). To contextualize results in the tumor microenvironment, we interrogated single-cell RNA-seq datasets via TISCH2 and explored pharmacogenomic associations using GDSC. Mechanistic plausibility was tested in A549 lung adenocarcinoma cells using FTMT overexpression followed by qPCR and Western blotting.

Results

Genetically predicted higher FTMT levels were associated with reduced NSCLC risk (IVW OR per 1-SD increase ≈ 0.91). Mediation MR suggested that MICB-related signals accounted for a modest proportion of the FTMT effect. Single-cell analyses showed FTMT enrichment in malignant epithelial cells, whereas MICB was expressed across multiple compartments. In vitro, FTMT overexpression increased MICB mRNA and protein abundance.

Conclusions

Integrating genetic evidence, tumor-context transcriptomics, and cell-based validation supports FTMT as a protective factor for NSCLC and points to a mitochondrial–immune axis involving MICB. Observed differences between blood-based genetic proxies and tumor-cell experiments are consistent with context-dependent regulation (e.g., circulating MICB can reflect shedding, whereas tumor-cell MICB reflects surface stress-ligand programs).